key: cord-0979097-l13m03je
authors: Cook, Nathan; Xu, Lingqing; Hegazy, Shaymaa; Wheeler, Bradley J.; Anderson, Adam R; Critelli, Nancy; Yost, Mary; McElroy, Anita K.; Shurin, Michael R.; Wheeler, Sarah E.
title: Multiplex assessment of SARS-CoV-2 antibodies improves assay sensitivity and correlation with neutralizing antibodies
date: 2021-08-26
journal: Clin Biochem
DOI: 10.1016/j.clinbiochem.2021.08.006
sha: 507f96a815d9a573f317bf873c562097387c28c7
doc_id: 979097
cord_uid: l13m03je

Objectives Detection of antibodies to multiple SARS-CoV-2 antigens in a single assay could increase diagnostic accuracy, differentiate vaccination from natural disease, and aid in retrospective exposure determination. Correlation of binding antibody assessment in clinical assays with neutralizing antibodies is needed to better understand the humoral response to SARS-CoV-2 infection and establish of correlates of protection. Methods A cohort of 752 samples was used to assess specificity, sensitivity, and comparison to 6 other Conformitè Europëenne serologic assays for the BioRad SARS-CoV-2 IgG multiplex assay which measures receptor binding domain IgG (RBD), spike-S1 IgG (S1), spike-S2 IgG (S2), and nucleocapsid IgG (N). A subset of serial specimens from 14 patients was also tested for neutralizing antibodies (n=61). Results Specificity for RBD and S1 IgG was 99.4% (n=170) and 100% for S2 and N IgG (n=170) in a cohort selected for probable interference. Overall assay concordance with other assays was >93% for IgG and total antibody assays and reached 100% sensitivity for clinical concordance at >14 days as a multiplex assay. RBD and S1 binding antibody positivity demonstrated 79-95% agreement with the presence of neutralizing antibodies. Conclusions The BioRad SARS-CoV-2 IgG assay is comparable to existing assays, and achieved 100% sensitivity when all markers were included. The ability to measure antibodies against spike and nucleocapsid proteins simultaneously may be advantageous for complex clinical presentations, epidemiologic research, and in decisions regarding infection prevention strategies. Additional independent validations are needed to further determine binding antibody and neutralizing antibody correlations.

decisions regarding infection prevention strategies. Additional independent validations are needed to further determine binding antibody and neutralizing antibody correlations.

SARS-CoV-2 causes COVID-19 which is a major cause of acute respiratory distress syndrome. The COVID-19 pandemic has necessitated emergency use authorization (EUA) of diagnostic testing in the US and similar expedited approvals worldwide, leading to testing that may be lacking sufficient data for appropriate clinical utilization. Serologic detection of SARS-CoV-2 began in early 2020 with poorly characterized assays and inappropriate claims regarding the utility and accuracy of SARS-CoV-2 serology which led to initial distrust of serologic assays [1, 2] . In the months following, independent assessments demonstrated clinical utility and additional manufacturers contributed to the development of important clinical assays. Due to the continued expedited reviews of SARS-CoV-2 diagnostics, independent and well-defined validation of commercially available assays remains of critical importance.

As the COVID-19 pandemic progresses into a vaccine-available era, the utility of SARS-CoV-2 serology is also evolving. Pre-vaccine, assays were used for complex or delayed clinical presentations, infection prevention assessments, epidemiologic research, and convalescent plasma donation determination [2] . Most assays use a single antigen to detect specific antibodies in patient blood. The most common antigens of interest have been nucleocapsid (N) and receptor binding domain (RBD). Other antigens from SARS-CoV-2 include spike 1 (S1) and spike 2 (S2) which correspond to the N-and C-terminals of the spike protein respectively. Assays have also varied in detection of immunoglobulin classes. Before the availability of a SARS-CoV-2 vaccine, assays against RBD seemed of particular interest as RBD is required for viral entry into the cell and is the target of neutralizing antibodies [3] . The first vaccines available in the US used spike protein as antigen which is detectable in RBD and S1 and S2 serologic assays [4, 5] . This situation is similar to our assessment of hepatitis B (HepB), where anti-surface antigen antibody can be present following vaccination and natural disease and other tests are required to differentiate between the two states, though primary diagnosis for SARS-CoV-2 infection is through nucleic acid testing. The need to differentiate between natural disease and vaccine response is particularly important for epidemiologic studies. Retrospective determination of natural or vaccine positive serology is also potentially useful for infection prevention, as well as research assessing long term COVID-19 health outcomes, asymptomatic cases, or vaccine efficacy. The ability to detect antibodies to multiple SARS-CoV-2 proteins in a single assay would allow for this functionality.

Quantification of antibodies against SARS-CoV-2 proteins could help to establish an immune correlate of protection as has been done for many other vaccines (eg -MMR, HepB). Further, it is critical that we assess how these binding antibody assays correlate with neutralizing antibodies to inform clinical utility of serologic testing [6, 7] .

We used a defined cohort of 752 samples to assess specificity, sensitivity, and comparison to other commercially available serologic assays for the BioRad SARS-CoV-2 IgG multiplex assay and further assessed a subset of 61 samples for neutralizing antibody titer.

Remnant sera and data from specimens received in the University of Pittsburgh Lithium heparin plasma and serum samples with separator gel were centrifuged and stored at 4°C for up to 2 weeks before storage at -20°C. Samples were banked at -20°C for up to 11 months before analysis.

SARS-CoV-2 antibody assays were performed in CLIA certified high-complexity clinical laboratories at UPMC. The comparison sample cohort testing is previously published [8] . All assays, abbreviations used, manufacturers, antigens, units, positivity thresholds, and antibody types detected are listed in Table 1 . Assays were performed according to manufacturer's instructions. All assays use units that are generated by comparison to an internal standard, when referring to assay results collectively we refer to these units as 'index values' for simplicity. All assays are qualitative assays except the BioRad assay which is semi-quantitative with qualitative interpretation.

Detection of SARS-CoV-2 RNA was reported in the EMR as standard clinical testing and is performed using the Cepheid GeneXpert or a lab developed test based on the CDC protocol [9] . Measurement of specificity samples for autoimmune and infectious disease serologies in the comparison cohort is described elsewhere [8] .

FRNT assays were performed as previously described [10] . Briefly heatinactivated samples were diluted in DMEM and then incubated with 100 FFU of SARS-CoV-2 (University of Pittsburgh clinical isolate June 2020). Following incubation, samples were inoculated onto Vero E6 cells then overlayed with carboxymethylceluose.

After 18h incubation plates were washed, fixed, permeabilized, blocked and foci were stained using a custom anti-SARS-CoV-2 N polyclonal antibody. Bound antibody was detected using goat anti-rabbit IgG HRP followed by TMB-H Peroxidase Substrate. Foci were imaged, counted, and processed using an ImmunoSpot Counter (CTL). Foci were counted in experimental wells and compared to control wells. The dilution of serum at which 80% of foci are neutralized is reported as the FRNT 80 . 

The specificity of the multiplex assay was tested against an existing cohort of samples selected for a high likelihood of cross-reactivity due to other co-morbidities (n = 170, Table S1 ). These samples were collected before SARS-CoV-2 was geographically present and have been previously described [8] . Prior testing by several platforms is described elsewhere and overall 92% of the originally tested samples were available for this study [8] . Both S2 IgG and N IgG demonstrated 100% specificity and RBD IgG and S1 IgG demonstrated cross reactivity on one sample giving a specificity of 99.4%. This cross-reactive sample was molecularly positive for one of the common coronaviruses and was also found to be serologically reactive by three of six previously tested platforms [8] .

To assess assay analytical sensitivity and generally evaluate semi-quantitative claims, serial samples from patients who were hospitalized and had remnant samples available for at least 3 timepoints (n=27 , Table S2 ) were tested. Ten of these patients were previously tested for SARS-CoV-2 antibodies by several platforms [8] . When seroconversion occurred on a day for which there was no available sample, the average of the two available samples before and after seroconversion was taken as an estimate. In cases where it was possible to see one or two markers become reactive first (n=17) N IgG was most often the first detectable (n=9) followed by RBD IgG (n=6), S2 IgG (n=4) and S1 IgG (n=3). Notably all three S1 IgG cases were detectable the same day as RBD IgG. In some patients, RBD was detected first and significantly earlier, than other antigens with N detection occurring late. In other patients N IgG appeared significantly earlier than others ( Figure S1 , Table S2 ). Overall, we found that patient U/mL values increased over time with a plateau in some patients as would be anticipated in an assay with semi-quantitative values ( Figure S2 ).

We next assessed all patients with days from symptom onset or PCR and plotted on a logarithmic scale to better assess U/mL levels over time for all IgG components ( Figure 1 ). As anticipated S1 IgG often mirrors RBD IgG. Table S3 ).

Using both the comparison and routine run samples we assessed concordance between assays and clinical diagnosis ( The multiplex assays are semi-quantitative and the other assays we compared against are qualitative but our prior work has demonstrated that the index values for these assays also appear to be semi-quantitative [8, 11] . Using nine of the ten patients with serial samples from the comparison cohort we assessed comparison between assays when the positive cutoff was normalized to an index value of 1.0 ( Figure 2 ). The tenth patient had only three timepoints and demonstrated a similar trend and is included in the supplementary material ( Figure S3 ). We found that assays detecting antibodies against RBD trended together. Trends in assays detecting antibodies to N showed more discordance in their trends, though one detected total antibodies and the other IgG specifically.

Neutralizing antibodies have been found to correlate inversely with viral shedding and are one of the surrogate markers often used as part of disease immunity assessment [12, 13] . We therefore used a subset of serial samples from 14 patients (n=61) hospitalized and positive for COVID-19 to assess correlation between binding and neutralizing antibodies. RBD and S1 assays demonstrated higher index values with higher neutralizing antibody titers overall (Figure 3 A, B) . N and S2 assays had modest increases in index values with increasing neutralization titers (Figure 3 (Table 3, 95% CI Table   S5 ). Negative agreement had few samples as neutralizing antibodies were found in samples that were negative by binding antibody assays, however no sample was positive for neutralizing antibodies and negative for all binding antibodies (Table S6 ).

We assessed the BioRad multiplex SARS-CoV-2 IgG assay to determine assay comparability to our existing methodologies and overall performance characteristics in natural disease. The introduction of SARS-CoV-2 vaccines is a needed shift in our response to this global pandemic but brings with it new challenges and opportunities for the use of serologic testing in SARS-CoV-2. Many SARS-CoV-2 vaccines use the spike antigen to elicit an immune response [5] . In assays that detect antibodies against the RBD, S1 or S2 there will likely be reactivity in vaccinees, however N reactivity should be present only in natural disease [4, 5] . Assays that can provide semiquantitative results that can differentiate between natural disease and vaccine responses are desirable to aid in epidemiologic research, assess long term effects of natural disease, and assess immune response to vaccination in at risk persons with immune dysregulation. A single assay that can provide all of this information reduces the need for multiple assay maintenance and sample volume. Though it should be noted that the use of widespread serologic testing after vaccination is not currently recommended and there are limitations in our understanding of all of the immune correlates of protection after vaccination [14] .

We found that RBD, S1, S2, and N IgG all had excellent specificity which was similar to that of other current EUA and CE assays [8, 15, 16] . We observed possible cross-reactivity in one sample for which the patient had a nasopharyngeal swab positive for one of the common coronaviruses in the RBD and S1 IgG. Our prior work with this sample found that it demonstrated SARS-CoV-2 antibody cross-reactivity in three of six platforms [8] . Due to the timing of this sample we cannot exclude true SARS-CoV-2 infection from consideration as it was drawn before SARS-CoV-2 was geographically present but not before December 2019. The patient history demonstrated no travel or contact concerns, but SARS-CoV-2 testing was not yet available to definitively exclude infection. Some antibody cross-reactivity in conserved epitopes between the common coronaviruses and SARS-CoV-2 has been found in general serology studies, though these epitopes are located in S2 and N where we saw no cross-reactivity [17] .

In assessing timing of seroconversion by days from symptom onset we found that N IgG was most often the first to become detectable but also had significantly delayed responses in some patients. This heterogeneity in serologic conversion for different antigens may be an effect of disease severity, or other correlates for which we do not have information and is an area of future interest. Despite the significant delays in detection of N IgG during the seroconversion window, it appears to have strong clinical sensitivity in detecting prior infection at >14 days and misses very few samples at >30 days. These findings are in keeping with other work [8, 12, 15, 16, [18] [19] [20] . This makes both RBD IgG and N IgG helpful in convalescent plasma donation screening and determination of natural disease history in the setting of vaccination with spike protein specific vaccines. Some clinical assays have poorer detection of prior SARS-CoV-2 infection at >30 days [8] and we found that S2 IgG had poor detection overall.

We found overall concordance between several existing CE and EUA SARS-CoV-2 serologic assays using the same antigens as this multiplex assay to be clinically acceptable. Using all four multiplex assays together yielded 100% concordance with both PCR positivity and Clinical Diagnosis at >14 days. In our prior work and others with both RBD and N serologic assays, no assay achieved 100% concordance with clinical markers [8, 11, 15, 16, 20] . Agreement between assays with the same antigen was higher than we anticipated and adjusting all assays for a positivity cutoff of approximately 1.0 index value demonstrated similar trending during seroconversion. The seroconversion U/mL longitudinal increase in the multiplex assay reinforced the semi-quantitative nature of this assay, which corresponded with index values for existing qualitative assays. Due to the highly infectious nature of SARS-CoV-2 and the extended time period for which RNA testing can remain positive, antibody testing has emerged as a useful tool in infection prevention [12, 13] . Determination of removal of airborne precautions for inpatients or acceptability of transfer to skilled nursing facilities is a difficult decision resting with infection preventionists. Limited work to date indicates that the presence of neutralizing antibodies correlates with a decrease in ability to culture SARS-CoV-2 from nasal swabs, thus a threshold that reflects the presence of neutralizing antibodies may also be an important step for improving our control of viral spread in medical care settings [12, 13] . Most clinical serology assays assess patient samples for binding antibodies and data demonstrating how well binding antibodies correlate with neutralizing antibodies both during seroconversion and over time continues to accrue [12, [21] [22] [23] . Specifically, most neutralizing antibody literature uses pseudoviral methodologies rather than the gold standard plaque and focus reduction neutralization tests, though additional work utilizing FRNT is emerging with mixed findings [24] [25] [26] .

We found that positive agreement between FRNT 80 neutralizing assay and antibodies to RBD ranged from 83-95% across binding assays. S1 also demonstrated high positive agreement between neutralization and binding assays ranging from 79-82%. Positive agreement was highest between neutralizing antibodies and the SiemensV at 95% (95% CI 82.7-98.5) and second by the full multiplex assay qualitative result at 91% (95% CI 80.1-96.0), though 95% confidence intervals overlapped for all assays. For discrepancies between neutralizing and binding antibodies it was most common that neutralizing antibodies were detected while binding antibody assays were not yet reactive. We expect RBD antibodies, rather than S1, S2 or N, to correlate better with neutralizing antibody assays as these are thought to be the principal drivers in virus neutralization [3] . Recent work by other groups has found reasonable correlation between FRNT and commercial binding antibody assays with various antigen targets, FRNT 50 rather than FRNT 80 has been used for those correlates [25, 26] . Though some groups have reported insufficient correlation to consider binding antibody assays reflective of functional antibody response [24] . This has important implications for determining immune correlates of protection for binding antibodies for both natural disease and vaccine induced immunity.

Overall, we found the BioRad SARS-CoV-2 IgG assay to be acceptable for clinical use and comparable to existing CE and EUA serologic assays. This work has several limitations including: additional freeze-thaw cycle for samples assayed by the BR and neutralization assays; relatively small cohort size, particularly for FRNT; lack of demographic and comorbidity information. The ability to measure multiple analytes simultaneously may be advantageous for complex clinical presentations, epidemiologic research to differentiate between natural disease and some vaccines, and in some decisions regarding infection prevention strategies. Additional independent validations are needed to further determine RBD binding antibody and neutralizing antibody correlations and corroborate these findings. All cohort specimens which were tested PCR positive or recorded as positive in the electronic medical record. Note this is a subset of 'All specimens' assayed by both the listed assays. c All specimens collected >14 days from tested PCR positive or recorded as positive in the electronic medical record. Note this is a subset of 'All specimens' assayed by both the listed assays. d All cohort specimens which were tested PCR positive. e All cohort specimens which were tested PCR positive or recorded as positive in the electronic medical record. 

The FDA's Experience with Covid-19 Antibody Tests

The Role of Antibody Testing for SARS-CoV-2: Is There One?

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Variable Performance in 6 Commercial SARS-CoV-2 Antibody Assays May Affect Convalescent Plasma and Seroprevalence Screening

-nCoV) Real-Time RT-PCR Diagnostic Panel For Emergency Use Only Instructions for Use

A Cross-Sectional Study of SARS-CoV-2 Seroprevalence between Fall

Evaluation of SARS-CoV-2 prototype serologic test in hospitalized patients

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

van der Eijk, Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC

Performance characteristics of four high-throughput immunoassays for detection of igg antibodies against sars-cov-2

Differences in Performance Characteristics Among Four High-Throughput Assays for the Detection of Antibodies Against SARS-CoV-2 Using a Common Set of Patient Samples

Epitoperesolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses

Evaluation of SARS-CoV-2 serology assays reveals a range of test performance

Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation

Clinical evaluation of five different automated SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Characterization of <scp>100</scp> sequential <scp>SARS-CoV-2</scp> convalescent plasma donations

Multicenter evaluation of the clinical performance and the neutralizing antibody activity prediction properties of 10 high-throughput serological assays used in clinical laboratories

Evaluation of High-Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization Test

Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays

Green figures and lines represent platforms with nucleocapsid associated antibody detection. RBD: receptor binding domain

EuroIGA and EuroIGG have an assay positivity cutoff of 1.1, and the dotted line approximates this. (A) Binding assays against the receptor binding domain are plotted. (B) Binding assays against the S1 protein are plotted. (C) Binding assays against nucleocapsid and S2 protein are plotted